Cell signaling in cutaneous T-cell lymphoma microenvironment: promising targets for molecular-specific treatment

Area of Science:

• Dermatology
• Oncology
• Immunology

Background:

• Cutaneous T-cell lymphomas (CTCL) are cancers of T cells in the skin.
• The CTCL microenvironment features altered cell interactions and signaling pathways.
• Understanding these alterations is key to disease progression and therapeutic strategies.

Purpose of the Study:

• To review molecular and genetic findings in CTCL, focusing on mycosis fungoides (MF) and Sézary syndrome (SS).
• To highlight modifications in key signaling pathways involved in CTCL pathogenesis.
• To identify potential molecular biomarkers and therapeutic targets.

Main Methods:

• Review of recent molecular and genetic findings in CTCL.
• Focus on signaling pathways regulating cell proliferation, immune response, and tissue conditions.
• Analysis of pathways including MAP kinases, PI3K/Akt, TCR, TLR, JAK/STAT, NF-kB, extracellular matrix remodeling, hypoxia, and angiogenesis.

Main Results:

• CTCL involves dysregulated signaling pathways crucial for T-cell proliferation, survival, migration, and immune evasion.
• Specific pathways identified include those for cell growth (MAPK, PI3K/Akt), immune response (TCR, TLR, JAK/STAT, NF-kB), and tissue modulation (ECM remodeling, hypoxia, angiogenesis).
• These alterations create a pro-tumor microenvironment facilitating disease progression.

Conclusions:

• Signaling network alterations are central to CTCL pathogenesis, promoting malignant T-cell survival and immune suppression.
• Targeting key proteins within these pathways offers potential therapeutic avenues for CTCL.
• Existing molecules used in research and other clinical indications may be repurposed for CTCL treatment.